SEC filing record
Primary Source · SEC.gov

Aadi Bioscience, Inc.

2025 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2025-03-182 events: 1 new form d filer, 1 large raiseLast filing 2025-03-18

Raised

$100M

Investors

17

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Aadi Bioscience, Inc. is a Delaware corporation that filed a Form D with the SEC on March 18, 2025 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Aadi Bioscience, Inc. reported $100,002,392 sold from 17 investors of a $100,002,392 total offering as of the Form D filed March 18, 2025. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Jefferies LLC (CRD 2347), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $4,335,553 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 2 Headquarters Plaza, East Building, 11th Floor, Morristown, NJ 07960.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001422142
Entity NameAadi Bioscience, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address2 Headquarters Plaza, East Building, 11th Floor, Morristown, NJ 07960
Phone(551) 321-2234
Former NamesAadi Bioscience, Inc. (until March 18, 2025); Aerpio Pharmaceuticals, Inc. (until August 23, 2021); ZETA ACQUISITION CORP II (until March 13, 2017)
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateMarch 4, 2025
Filing DateMarch 18, 2025
Accession Number0002018445-25-000002
Total Offering Amount$100,002,392
Total Amount Sold$100,002,392
Amount Remaining$0
Total Investors17
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$4,335,553 (to Jefferies LLC)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)NJ
Amendment Count5 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

2

latest Mar 18, 2025

Critical / warning

0 / 0

2 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

5

closed, lapsed

Latest event New filer · Mar 18, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 2 filing events with values and deltas, latest 2025-03-18, and alerts on the next one
  • 5 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2025-03-18: 5 related persons added and 2 removed against the filing of 2022-10-11; 13 now listed. The names are in the Terminal feed.

Dave Lennon

Executive Officer, Director · MORRISTOWN, NJ

Scott Giacobello

Executive Officer · MORRISTOWN, NJ

Caley Castelein

Director · MORRISTOWN, NJ

Neil Desai

Director · MORRISTOWN, NJ

Behzad Aghazadeh

Director · MORRISTOWN, NJ

Anupam Dalal

Director · MORRISTOWN, NJ

Karin Hehenberger

Director · MORRISTOWN, NJ

Mohammad Hirmand

Director · MORRISTOWN, NJ

Richard Maroun

Director · MORRISTOWN, NJ

Emma Reeve

Director · MORRISTOWN, NJ

Baiteng Zhao

Director · MORRISTOWN, NJ

Bryan Ball

Executive Officer · MORRISTOWN, NJ

David Dornan

Executive Officer · MORRISTOWN, NJ

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Jefferies LLCCRD 2347 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

Questions About Aadi Bioscience, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Aadi Bioscience, Inc.?

Aadi Bioscience, Inc. is a Delaware corporation that filed a Form D with the SEC on March 18, 2025 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is Aadi Bioscience, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Aadi Bioscience, Inc. filed a Form D with the SEC on March 18, 2025 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $100,002,392 sold to 17 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Aadi Bioscience, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Aadi Bioscience, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Aadi Bioscience, Inc. raised?

Aadi Bioscience, Inc. reported $100,002,392 sold from 17 investors of a $100,002,392 total offering as of the Form D filed March 18, 2025.

Who can invest in Aadi Bioscience, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Aadi Bioscience, Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Aadi Bioscience, Inc. and how are they paid?

The Form D names Jefferies LLC (CRD 2347), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $4,335,553 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Aadi Bioscience, Inc.?

The Form D lists 13 related persons: Dave Lennon, executive officer, director; Scott Giacobello, executive officer; Caley Castelein, director; Neil Desai, director; Behzad Aghazadeh, director; Anupam Dalal, director; Karin Hehenberger, director; Mohammad Hirmand, director, and 5 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Aadi Bioscience, Inc. located?

The issuer's address on its SEC filings is 2 Headquarters Plaza, East Building, 11th Floor, Morristown, NJ 07960. Its phone number of record is 551-321-2234. It is organized under the laws of Delaware.

How long is the Aadi Bioscience, Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is Aadi Bioscience, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.